首页 | 本学科首页   官方微博 | 高级检索  
     

荷EL4肿瘤小鼠模型的建立及美法仑抑瘤作用免疫机制的探讨
引用本文:李墨林,李传刚,舒晓宏,贾玉杰,秦志海. 荷EL4肿瘤小鼠模型的建立及美法仑抑瘤作用免疫机制的探讨[J]. 细胞与分子免疫学杂志, 2006, 22(2): 235-238
作者姓名:李墨林  李传刚  舒晓宏  贾玉杰  秦志海
作者单位:1. 大连医科大学基础医学院病理生理学教研室,辽宁,大连,116027
2. 大连医科大学附属二院外科,辽宁,大连,116027
3. 大连医科大学药学院,辽宁,大连,116027
4. 德国洪堡大学CBF肿瘤免疫实验室,德国,柏林,12200
基金项目:国家留学基金;辽宁省教育厅资助项目
摘    要:目的:建立荷小鼠淋巴瘤EL4的野生型C57BL/6小鼠及其裸鼠模型,探讨美法仑(melphalan)抑瘤作用的免疫机制。方法:给正常野生型C57BL/6小鼠皮下接种小鼠淋巴瘤EL4细胞,建立荷EL4肿瘤的小鼠模型。于野生型C57BL/6小鼠皮下接种瘤细胞后12d,经腹腔给荷瘤小鼠单次注射不同剂量的美法仑,找出美法仑可发挥最大的抑瘤作用,并能致使肿瘤消退、不再复发的最小使用剂量。然后再给野生型C57BL/6小鼠及其裸鼠(遗传背景相同)皮下同时接种小鼠淋巴瘤EL4细胞建立两种荷瘤小鼠模型。同样于接种瘤细胞后12d,经腹腔给两种荷瘤小鼠模型均注射可使野生型C57BL/6小鼠肿瘤消退、不再复发的最低剂量的美法仑,以正常野生型C57BL/6小鼠为对照,观察在T淋巴细胞缺陷的裸鼠体内美法仑的抑瘤作用。结果:注射7.5mg/kg美法仑治疗后,免疫功能正常的野生型C57BL/6荷瘤小鼠的肿瘤消退;而荷瘤C57BL/6裸鼠的肿瘤仍继续生长。结论:单一剂量的美法仑对荷淋巴瘤EL4小鼠具有明显的治疗作用,其作用的发挥需要T淋巴细胞的参与,可能与T细胞的杀伤作用有关。

关 键 词:淋巴瘤EL4细胞  美法仑  C57BL/6小鼠  肿瘤治疗
文章编号:1007-8738(2006)02-0235-04
收稿时间:2005-09-19
修稿时间:2005-12-22

Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan
LI Molin,LI Chuan-gang,SHU Xiao-hong,JIA Yu-jie,QIN Zhi-hai. Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan[J]. Chinese journal of cellular and molecular immunology, 2006, 22(2): 235-238
Authors:LI Molin  LI Chuan-gang  SHU Xiao-hong  JIA Yu-jie  QIN Zhi-hai
Affiliation:Pathophysiology department of Dalian Medical University, Dalian 116027, China
Abstract:AIM: To establish mouse lymphoma EL4 tumor-bearing mouse models in wild type C57BL/6 mice and nude C57BL/6 mice respectively, and to further investigate the immunological mechanisms of anti-tumor effect of melphalan. METHODS: Mouse lymphoma EL4 cells were inoculated subcutaneously into wild type C57BL/6 mice (immune-competent mice). Twelve days later, melphalan of different doses were administered intraperitoneally to treat these wild type C57BL/6 tuomr-bearing mice. Tumor sizes were observed and recorded subsequently to find out the minimal dose of melphalan that could cure the tuomr-bearing mice. Then the same amount of EL4 tumor cells were inoculated subcutaneously into wild type C57BL/6 mice and nude C57BL/6 mice (T cell-deficient mice) simultaneously, which had the same genetic background of C57BL/6. Twelve days later, melphalan of the minimal dose was given intraperitoneally to treat both the wild type and nude C57BL/6 tuomr-bearing mice. Tumor sizes were observed and recorded in these two different types of mice subsequently. RESULTS: A single dose of melphalan (7.5 mg/kg) could cure EL4 tumor-bearing wild type C57BL/6 mice, but could not induce tumor regression in EL4 tumor-bearing nude C57BL/6 mice. CONCLUSION: A single dose of melphalan has obvious anti-tumor effect on mouse lymphoma EL4 tumor-bearing wild type C57BL/6mice, which requires the involvement of T lymphocytes in the host probably related to their killing functions.
Keywords:mouse lymphoma EL4 cell  melphalan  C57BL/6 mouse  tomor therapy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号